- Title
- Metastatic melanoma treatment: combining old and new therapies
- Creator
- Davey, Ryan J.; van der Westhuizen, Andre; Bowden, Nikola A.
- Relation
- NHMRC.569317 http://purl.org/au-research/grants/nhmrc/569317
- Relation
- Critical Reviews in Oncology/Hematology Vol. 98, p. 242-253
- Publisher Link
- http://dx.doi.org/10.1016/j.critrevonc.2015.11.011
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2016
- Description
- Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very limited. Largely ineffective dacarbazine, temozolamide or fotemustine were the only agents in use for 35 years. In recent years, the development of molecularly targeted inhibitors in parallel with the development of checkpoint inhibition immunotherapies has rapidly improved the outcomes for metastatic melanoma patients. Despite these new therapies showing initial promise; resistance and poor duration of response have limited their effectiveness as monotherapies. Here we provide an overview of the history of melanoma treatment, as well as the current treatments in development. We also discuss the future of melanoma treatment as we go beyond monotherapies to a combinatorial approach. Combining older therapies with the new molecular and immunotherapies will be the most promising way forward for treatment of metastatic melanoma.
- Subject
- melanoma; treatment; targeted therapy; immunotherapy; combination therapy
- Identifier
- http://hdl.handle.net/1959.13/1345213
- Identifier
- uon:29594
- Identifier
- ISSN:1040-8428
- Language
- eng
- Reviewed
- Hits: 1331
- Visitors: 1511
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|